ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

ACS Plan New Study On Environmental, Lifestyle Factors

April 3, 1981

President Obama Visits NIH To Announce 12,000 Recovery Act Grants Worth $5 Billion

October 2, 2009

DeVita Emphasizes NCI Prevention In Statement To Senate Committee

February 15, 1980

DCT Concepts Approved

October 11, 1985

Letter to the Editors: Since 1992, Where Has All The OAM Grant Money Gone?

April 24, 1998

NCI Issues 8 Awards, 12 Feasibility Grants, In New SPORE Program

October 9, 1992